帕利佩里酸基晶用于改善生物制药特性:体外和体外评估
Mohammed Elmowafy1, Nabil K Alruwaili1, Omar Awad Alsaidan1
1Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia.
ACS omega
|September 29, 2025
概括
与氧化酸一起开发帕利皮里顿共晶,显著提高了溶解度和口服生物可用性. 这种共晶配方为改善帕利佩里的生物制药性质提供了一个有希望的解决方案.
科学领域:
- 制药科学 制药科学
- 药物运输 药物运输 药物运输
- 材料科学 材料科学 材料科学
背景情况:
- 帕利佩里是一种有效的抗精神病药物,但具有较差的溶解性和较低的口服生物利用性.
- 改善帕利佩里的生物制药性质对于其治疗疗效至关重要.
研究的目的:
- 开发使用短链酸作为共同形成剂的paliperidone共晶体.
- 为了提高帕利佩里的可溶性,溶解率和口服生物可用性.
主要方法:
- 使用各种短链酸的可晶选.
- 使用FTIR,DSC,PXRD和SEM进行表征.
- 与纯帕利皮里相比,体外溶解和体内生物可用性研究.
主要成果:
- 帕利佩里-酸共晶 (1: 2摩尔比) 显示了最高的溶解度 (9831±113μg/mL).
- 结构分析证实了晶的形成,揭示了键和较少的晶体状态.
- 与paliperidone悬浮剂相比,cocrystal表现出明显更快的溶解率和口服生物利用率的2.66倍增加.
结论:
- 与氧化酸一起形成帕利佩里合晶体是克服生物制药性质差的可行策略.
- 开发的共晶配方显示出更好的溶解性,溶解性和生物可用性,提供了一个有前途的治疗替代方案.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
200
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
200
Drug Product Performance: In Vitro–In Vivo Correlation
230
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
230
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
151
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
151
Factors Affecting Dissolution: Drug pKa, Lipophilicity and GI pH
3.0K
Drug absorption within the gastrointestinal (GI) tract is a complex process influenced by several critical factors, including the site pH, the drug's dissociation constant (pKa), and the drug's lipophilicity. The GI tract exhibits a pH gradient, with an acidic environment in the stomach and a more alkaline environment in the small intestine. This pH variation directly affects the ionization state of drugs.
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
A drug's pKa and the pH of the gastrointestinal (GI) tract play crucial roles...
3.0K
Biopharmaceutics and Pharmacokinetics: Overview
3.3K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
3.3K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
673
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
673


